AŽURIRANJE Hematologija / Onkologija 2024
ESMO kongres 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Koristite stariju verziju web-preglednika, pa se neke značajke možda neće ispravno prikazivati.
MINIMALNI Zahtjevi: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Resursi za sastanke 19. listopada 2023. OncologyPRO sada nudi resurse za sastanke: +3.000 slajdova i webcastova; sažetaka i ePostera.Pristup resursima.
OncologyPRO sada nudi resurse za sastanke: +3.000 slajdova i web prijenosa; sažetaka i ePostera.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 poboljšava rPFS za metastatske pacijente s rakom prostate otporne na kastraciju koji nisu uzimali taksane 23. listopada 2023. Nalazi ispitivanja PSMAfore ograničeni su činjenicom da ne pokazuju korist u smislu OS.
Registrirajte se za ulaznice ili kabine
Karta mjesta i hoteli u okolici
München - Holiday Inn München - centar grada, Bavarska, Njemačka München - Holiday Inn München - centar grada, Bavarska, Njemačka
Pretplati me